Veeva Systems Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended January 31, 2022; filed March 30, 2022. Veeva provides cloud software, data, analytics, and services, primarily to life sciences companies. It reported one operating segment and became a Delaware public benefit corporation on February 1, 2021.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $1.851 billion | $1.465 billion | +26% |
| Subscription revenue | $1.484 billion | $1.179 billion | +26% |
| Professional services and other revenue | $367 million | $286 million | +28% |
| Gross profit / margin | $1.347 billion / 73% | $1.056 billion / 72% | Margin +1 percentage point |
| Operating income / margin | $505 million / 27% | $378 million / 26% | +34% income |
| Net income / diluted EPS | $427 million / $2.63 | $380 million / $2.36 | +12% income |
| Operating cash flow | $764 million | $551 million | +$213 million |
- Subscription services were 80% of total revenue. Commercial Solutions generated 56% of revenue; R&D Solutions generated 44%. R&D’s share increased from 39% in FY2021.
- Gross margin improved mainly from a more favorable mix, including growth in higher-margin R&D solutions. Professional services gross margin was 24%, versus 21%.
- Net income grew more slowly than operating income, largely reflecting a higher effective tax rate: 16.6%, compared with 3.6%, primarily because of lower excess tax benefits from equity compensation and increased valuation allowances.
- At year-end, cash and cash equivalents were $1.138 billion and short-term investments were $1.238 billion, totaling about $2.4 billion. Current assets were $3.107 billion and current liabilities $841 million. The filing reports no borrowings or debt balance; liabilities included $732 million of deferred revenue and $55 million of lease liabilities.
- Investing activities used $346 million, primarily for net purchases of investments, acquisitions, and long-term assets. Financing activities used $4 million, including $55 million of employee tax payments for net-settled RSUs.
Changes, outlook, and management commentary
- Revenue growth slowed to 26% from 33% in FY2021. Management expects total and subscription revenue growth rates to decline further over time.
- Subscription revenue retention was 119%, down from 124%. The measure includes renewals, customer and user additions or reductions, and solution expansions or discontinuations.
- R&D subscription revenue increased by $173 million, compared with $132 million for Commercial Solutions. Management expects R&D to keep increasing as a share of revenue.
- Operating expenses rose 24% to $842 million. Management expects expenses and stock-based compensation to increase in absolute dollars, with operating expenses potentially increasing slightly as a share of revenue. Salary increases, higher hiring costs, product development, data acquisition, and litigation expenses are among the cited cost pressures. Stock-based compensation was $235 million.
- No specific full-year financial guidance is presented in the supplied filing text. Management cites continued product investment, hiring, and international expansion; it expects professional-services revenue to decline as a proportion of total revenue over time.
- COVID-19 had not materially negatively affected operating or financial performance to date, but effects remain uncertain. Management expected most anticipated life-sciences sales-representative reductions of roughly 10% to occur in FY2023, with some in FY2024; this could pressure CRM-related demand. Virtual-engagement products may benefit. Large in-person events were expected to resume during FY2023, subject to disruption.
- The company increased salaries for most employees by 5% effective September 1, 2021, citing inflation and competition for talent; it expected FY2023 annual compensation increases to exceed historical norms. Headcount reached 5,482, up 976 year over year, and attrition exceeded historical levels.
Risks, contingencies, and unusual items
- Material ongoing litigation includes IQVIA disputes involving trade-secret, antitrust, and data-use claims, and a Medidata trade-secret case scheduled for trial in July 2022. The company could not estimate a loss range for the cited matters. It also disclosed possible success-fee obligations to counsel for which no amount was accrued.
- Key business risks include reliance on life sciences customers and a concentrated group of large customers (the top 10 generated 31% of FY2022 revenue), intense competition, adoption of newer products, and restrictions on customers’ use of third-party data, particularly IQVIA data.
- Veeva CRM and related applications depend substantially on Salesforce technology. The agreement expires September 1, 2025, and limits where the company may sell its CRM solution; termination or non-renewal could require a costly platform transition.
- Cybersecurity, privacy, regulatory compliance, and third-party hosting disruptions could affect customer trust, renewals, and service delivery. The filing also highlights geopolitical and macroeconomic uncertainty, including Russia’s invasion of Ukraine and continuing COVID-19 effects.
- As a public benefit corporation, directors must balance stockholder financial interests with stakeholder interests and the stated public benefit purpose. The dual-class structure concentrated voting power: Class B shares had ten votes each, and automatic conversion to a single class was scheduled for October 15, 2023.
- The FY2022 effective tax rate rose materially. Management warned that the requirement to capitalize and amortize certain R&D costs, if not deferred or changed, could materially reduce cash flows beginning in FY2023.
- KPMG issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. Revenue recognition was identified as a critical audit matter because of the multiple offerings and systems involved.
Important facts for investors to verify
- Whether revenue growth, retention, and R&D Solutions’ increasing contribution remain consistent with management’s outlook.
- How customer renewal pricing, potential sales-representative reductions, and customer consolidation affect CRM subscriptions and top-customer concentration.
- Developments and potential financial exposure in the IQVIA and Medidata litigation; the filing does not provide a clear estimated loss range.
- Progress on newer products, including Veeva Data Cloud and Development Cloud offerings, and the associated investment and margin effects.
- Future tax cash-flow effects, compensation and stock-based compensation costs, and interest-rate exposure in the $2.4 billion investment portfolio.
- Execution and governance implications of the PBC structure and the scheduled end of the dual-class voting structure.